Show simple item record

AuthorRabbani, Naila
AuthorAdaikalakoteswari, Antonysunil
AuthorLarkin, James R.
AuthorPanagiotopoulos, Sianna
AuthorMacIsaac, Richard J.
AuthorYue, Dennis K.
AuthorFulcher, Gregory R.
AuthorRoberts, Matthew A.
AuthorThomas, Merlin
AuthorEkinci, Elif
AuthorThornalley, Paul J.
Available date2023-10-11T10:41:42Z
Publication Date2022-12-21
Publication NameInternational Journal of Molecular Sciences
Identifierhttp://dx.doi.org/10.3390/ijms24010152
CitationRabbani, N., Adaikalakoteswari, A., Larkin, J. R., Panagiotopoulos, S., MacIsaac, R. J., Yue, D. K., ... & Thornalley, P. J. (2022). Analysis of serum advanced glycation endproducts reveals methylglyoxal-derived advanced glycation MG-H1 free adduct is a risk marker in non-diabetic and diabetic chronic kidney disease. International Journal of Molecular Sciences, 24(1), 152.
ISSN1661-6596
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85145978373&origin=inward
URIhttp://hdl.handle.net/10576/48451
AbstractAccumulation of advanced glycation endproducts (AGEs) is linked to decline in renal function, particularly in patients with diabetes. Major forms of AGEs in serum are protein-bound AGEs and AGE free adducts. In this study, we assessed levels of AGEs in subjects with and without diabetes, with normal renal function and stages 2 to 4 chronic kidney disease (CKD), to identify which AGE has the greatest progressive change with decline in renal function and change in diabetes. We performed a cross-sectional study of patients with stages 2–4 CKD, with and without diabetes, and healthy controls (n = 135). Nine protein-bound and free adduct AGEs were quantified in serum. Most protein-bound AGEs increased moderately through stages 2–4 CKD whereas AGE free adducts increased markedly. Methylglyoxal-derived hydroimidazolone MG-H1 free adduct was the AGE most responsive to CKD status, increasing 8-fold and 30-fold in stage 4 CKD in patients without and with diabetes, respectively. MG-H1 Glomerular filtration flux was increased 5-fold in diabetes, likely reflecting increased methylglyoxal glycation status. We conclude that serum MG-H1 free adduct concentration was strongly related to stage of CKD and increased in diabetes status. Serum MG-H1 free adduct is a candidate AGE risk marker of non-diabetic and diabetic CKD.
SponsorThis research was funded by a research grant from: - National Health and Medical Research Council (NHMRC) # No. 310632 - Austin Hospital Medical Research Foundation Grant (2003) - Qatar Foundation, grant number QB14 - NR by Qatar University, grant number QU ERG-CMED-2020-1 - Sir Edward Weary Dunlop Medical Research Foundation, National Health and Medical Research Council (NHMRC), Medical Research Future Fund and MTP Connect, Australia.
Languageen
PublisherMultidisciplinary Digital Publishing Institute (MDPI)
Subjectchronic kidney disease
diabetes
estimated glomerular filtration rate
glycation
methylglyoxal
TitleAnalysis of Serum Advanced Glycation Endproducts Reveals Methylglyoxal-Derived Advanced Glycation MG-H1 Free Adduct Is a Risk Marker in Non-Diabetic and Diabetic Chronic Kidney Disease
TypeArticle
Issue Number1
Volume Number24
ESSN1422-0067
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record